[BriOnH]

MicroIslet Changes Strategy to Accelerate Xenotransplantation Clinical Trials

In adopting this new strategy, the Company will shift its attention away from previously planned allotransplantation trials in the United States. By focusing exclusively on xenotransplantation trials, the Company will be able to reduce its operating expenses and shrink its present workforce from 22 to 15 employees. Additionally, President & CEO James R. Gavin III, M.D., Ph.D. has volunteered to reduce his annual compensation from $600,000 to $400,000. This restructuring is expected to save the Company up to $3 million over the next 12 months.

In executing its new strategy, MicroIslet will become more closely associated with Jonathan R. T. Lakey, Ph.D., M.S.M., who is one of the developers of the Edmonton Protocol -- the ground-breaking technology used worldwide in the treatment of type 1 diabetes -- and who has been a member of the Company's Scientific Advisory Board since 2002. Dr. Lakey will work with the Company to set up and coordinate new trials outside of the United States. While at the University of Alberta in Edmonton, Canada, Dr. Lakey's team helped establish over 40 islet transplantation programs worldwide. "MicroIslet's relationship with Dr. Lakey has been ongoing for several years and we are looking forward to his increased involvement with the Company and his input and expertise in assisting MicroIslet in the rollout of its clinical trials using porcine islets," commented Dr. Gavin. "I am pleased to expand my involvement in MicroIslet and to work with Dr. Gavin and the MicroIslet team to use this exciting technology to help people with diabetes all over the world," stated Dr. Lakey.

All I can say is that I am glad I dumped my microislet stocks when they were a $1.90 / share. Glad to see they are still trying. I hope they can contribute to a better therapy.